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correction. A simple Markov model was built to illustrate the impact of the half-
cycle correction, and to demonstrate how a more accurate correction factor can be
applied to models. RESULTS: Half-cycle corrections appear to be used routinely in
Markov models. In nearly all cases, the so-called “correction” is applied without
due consideration of the implications. Two major flaws were identified with the
approach. The first, mathematical, flaw is that the half-cycle correction approach
assumes that all events occur at the mid-point of each cycle. It can be demon-
strated that, for one-directional events (such as death), events will be more likely to
occur in the first half of the cycle since more patients will be exposed to the event
at the start of the cycle, and the number of patients ‘at risk’ falls throughout the
cycle. The second flaw is that, for many events, the implications of the event may
not actually become apparent until the next cycle. For instance, in oncology, the
increased costs associated with disease progression will not occur until progres-
sion is confirmed, which may only happen at regular routine follow-up visits.
CONCLUSIONS: Half-cycle corrections are frequently applied inappropriately in
modelling. This study has produced two key recommendations to generate more
accurate outcomes and to avoid biases in decision analytic models.
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OBJECTIVES: To define the extent to which using the EQ-5D versus disease-specific
instruments is critical in overall cost-effectiveness assessments, specifically re-
garding cost-utility. METHODS: Five ISPOR therapeutic areas (TAs) were randomly
selected, and literature research found on PubMed for the UK, as well as other
European publications, to retrieve publically available data on health state utility
scores in the respective TAs. Data were extracted into a database and various
model structures reconstructed in order to determine the impact of different HR-
QoL instruments on overall cost-effectiveness. Standard Monte Carlo techniques
were applied to generate simulations, informing both the expected cost-effective-
ness and its associated uncertainty. Cost-utility as well as net monetary / health
benefit were considered, based on willingness-to-pay for a QALY values ranging
from zero to €100,000. Incremental cost-utility scatter-plots as well as cost-effec-
tiveness acceptability curves were generated to illustrate how the results differ
both deterministically and probabilistically. RESULTS: The mean percentage
change in the cost-utility ratio across all five disease areas was app. 29% (a 95%
confidence interval ranging from21% to42%). Similar but even stronger results
were found when using incremental net monetary benefit measures. The thera-
peutic area with the most significant difference was oncology (36.5%), and the least
significant was cardiovascular (19%). Other TAs were COPD, Parkinson’s disease,
and obesity. CONCLUSIONS: It was consistently found that cost-effectiveness re-
sults differed significantly when different HR-QoL measures were used. Since dis-
ease-specific instruments employ more sensitive criteria than generic ones, they
generate more favourable cost-effectiveness results. Comparing the results of both
generic and specific indicators in structural sensitivity analyses appears to be im-
perative to assess the consistency of value judgements derived from quantitative
modelling.
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OBJECTIVES: Monte Carlo simulations are driven by the generation of pseudo ran-
dom numbers (PRN). Testing the effectiveness of PRN generators is rarely under-
taken yet any systematic pattern or bias has implications for simulation run time
and accuracy. The objective of this study was to compare two commonly used PRN
in an applied setting to illustrate potential implications of low performance.
METHODS: The IMS Core Diabetes Model (CDM) was used to explore their precision
in detecting the onset of end stage renal disease (ESRD using the MS-Visual C
2008 PRN generator (MSG) and Mersenne Twister generator (MTG). One-year prob-
abilities of ESRD for a 65 year old female smoker were generated with a systolic
blood pressure (SBP) of 135 mmHG (p0.000363) and 140 mmHg (p0.000444). The
expected one-year incidence was compared to probabilistic observations in the
CDM for both PRN generators. RESULTS: The expected yearly incidence of ESRD
was 0.0363% (SBP 135 mmHg) and 0.0444% (SBP (140mmHG). Monte Carlo estimates
were 0.0379% and 0.0477% using the MSG and 0.0239% for both SBP values using the
MTG. The MSG overestimated expected rates by 4.41% and 7.4%; the MTG under-
estimated the probability of ESRD by 34.16% and 46.17% SBP for 135mmHG and
140mmHg, respectively. The deterministic relative increase in incidence of ESRD
(22.3%) associated with a 5mmHg increment in SBP was similar to the MSG (25.8%);
using the MTG resulted in a 0% increase in the probability of ESRD. Analysis of the
frequency distribution of the MTG displayed areas sparsely populated with random
variates. CONCLUSIONS: The two PRN generators tested in this analysis produced
substantially different results. The differences between the two PRN algorithms
were most apparent when predicting relatively rare events, such ESRD. When as-
sessing the internal validity of Monte Carlo simulations the efficieny and robust-
ness of PRN generators should not be assumed.
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OBJECTIVES: In health economic modeling the role of probabilistic sensitivity anal-
ysis (PSA) is to assess the uncertainty of model predictions with respect to the
underlying parameter uncertainty. However, in Monte Carlo simulation parameter
uncertainty coincides with and cannot be distinguished from random noise, Monte
Carlo error (MCE). The objective of this study was to quantify the minimum run
time requirements to reduce MCE to acceptable levels. METHODS: An established
and validated model, the IMS CORE diabetes model (CDM), was used to compare
outcome variability of bootstrap simulations with 1000 repetitions and increasing
number of patients ranging from 2500 to 100000. Model projections were defined to
evaluate the cost effectiveness of two hypothetical interventions with differences
in clinical effectiveness of 0.5% HbA1c and a 2kg weight change in favor of the
treatment vs. control arm. Each simulation was performed in three ways; 1st where
no parameter sampling was applied, 2nd and 3rd where parameters were sampled
around 5% (SE based PSA) and 25% (SD based PSA) of their mean values, respec-
tively. The degree of MCE was determined according to the ratio of the confidence
ranges (ICER per QALY) of the non sampling analyses versus PSA. RESULTS: The
proportion of Monte Carlo error contained in overall ICER variability for simula-
tions with increasing number of patients (2500, 5000, 10000, 25000, 50000 and
100000) was found at 110%, 107%, 73%, 54%, 45% and 32% for SE based PSA and 80%,
80%, 37%, 13%, 9%, and 6% for SD based PSA. CONCLUSIONS: Run time require-
ments to reduce MCE are lower whenever the uncertainty of included parameters
is increased. Hypothesizing that not more than 40% of overall outcome variability
should be attributable to MCE, the minimum run time requirement was found at
100000 and 10000 patients for SE and SD based PSA, respectively.
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OBJECTIVES: The use of rhinitis total symptom scores (RTSS) is the recommended
method for documenting clinical effect of interventions in allergic rhinitis and
conjunctivitis. For cost utility analysis a patient preference measure (health state
utility) is needed. We explore whether the disutility of allergic rhinitis can be esti-
mated from RTSS. METHODS: We explored the properties of the RTSS and com-
pared these to the properties of the Rhinitis Symptoms Utility Index (RSUI) - a
multi-attribute utility function of rhinitis health states. Furthermore, we simulated
the outcome of a 2 week period with allergic rhinitis and compared the variation in
RSUI associated with each RTSS score to minimal important difference (MID) for
utility.RESULTS:RTSS is a linear mapping of daily reported rhinitis symptoms with
respect to frequency, type, and severity of symptoms. RSUI is multiplicative map-
ping of frequency, type and severity. This makes the RSUI a non-monotone map-
ping of RTSS which rules out direct one-to-one mapping from RTSS score to RSUI
utility score. The simulation showed that a specific RTSS score can result in very
different RSUI values; e.g. a RTSS score of 2.21 (fairly low symptom load) can be
associated with a RSUI in the range from 0.376 to 0.784. Since the span of possible
RSUI associated with each RTSS score is larger than the MID for utility by any
standards, no approximated mapping is not possible without making further as-
sumption on type of symptoms. CONCLUSIONS: The RTSS is a standard, recom-
mended measure of clinical effect in rhinitis and conjunctivitis intervention stud-
ies; however, further research is needed before patient health state preferences
and utility gains from interventions can be estimated from RTSS. These findings
emphasize the importance of using validated methods/tools when estimating and
comparing utility gains from separate interventions.
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OBJECTIVES: The use of patient level data (PLD) within cost-effectiveness models
offers the potential to analyse the relationship between individual input profiles
and predicted output. The objective of this study was to ascertain if particular PLD
input profiles were predictive of cost effectiveness sub-groups in Type 2 diabetes
mellitus (T2DM) subjects.METHODS: This study used the IMS Core Diabetes Model
(CDM), a validated and established diabetes model to evaluate the cost effective-
ness of a new 2ndline oral therapy (Treatment) compared to metformin sulpho-
nylurea (Control). Delta treatment effects (favouring Treatment) were a 0.5% HbA1c
reduction, 2kg weight change and a difference in symptomatic hypoglycaemia of
0.9/100 patient years. Annual diabetes specific therapy cost was £455 (Treatment)
versus £70 (Control). A PLD extract was obtained from NHANES over the period of
1999 to 2008 of T2DM subjects treated with oral therapy only. Costs (2010 UK£) and
benefits were discounted at 3.5%. Analysis of input/output data was undertaken
using R. RESULTS: PLD for 1,858 T2DM subjects from NHANES were obtained with
mean age 63.6 years of which 53% were male. Mean estimated cost per QALY of
Treatment versus Control was £6,111. Multivariate logistic regression identified age
(p0.05), SBP (p0.001) and HbA1c (p0.001) as model input variables significantly
associated with cost effectiveness at a willingness to pay (WTP) threshold of
£20,000. HbA1c was linearly and negatively correlated with incremental cost
(£569 per 1% increase (p0.001)). Subjects with baseline HbA1c7.4% had signif-
icantly lower incremental costs compared to those £ 7.4% (£ 1,205 versus £3,462
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respectively) and higher incremental QALY benefits (0.18 versus 0.15 respectively.
CONCLUSIONS: The identification of patient characteristics associated with
greater potential for health gain and reduced cost is an important goal. The anal-
ysis of PLD alongside simulation model output provides an additional mechanism
for informing health care decision-making.
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OBJECTIVES: Performing face validation and internal validation of health eco-
nomic models is recommended by various guidelines, including ISPOR, in model
development and is essential in determining a model’s credibility. Using third
parties – individuals outside of the model building process with no stake in model
results – is considered a best practice when conducting these validations. Yet the
rate at which published models follow this practice is unknown. This study reviews
the extent to which third parties were reported used to conduct face and internal
validity in published literature. METHODS: The study reviewed 100 health eco-
nomic models chosen randomly from published peer-reviewed health economic
literature within the last eight years. Decision analysis, Markov models, and dis-
crete event simulation models were included in the review. Each model was re-
viewed to determine the extent to which face validation and internal validation
were performed. Next, it was noted if these validations were performed by third
parties. Surveys were conducted with a subsample of models not reporting valida-
tion to determine if: 1) validation was performed but not reported; 2) if unreported
validation was performed by a third party; 3) any reason(s ) for not performing
validation; and 4) reasons for not using third parties. RESULTS: Third party face
validation and internal validation were each reported in less than one-third of the
studies reviewed. Survey results also found that third party validation was seldom
performed. Reasons for not performing third party validations included: believing
that third party validation was not necessary, time constraints, and budget
constraints. CONCLUSIONS: While considered a best practice, third party face and
internal validations are seldom performed on published economic models. Creat-
ing more awareness regarding this best practice may increase utilization of third
parties. Finding ways to perform these validations in a less costly and more timely
manner may increase usage as well.
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OBJECTIVES: To develop a conceptual model (CM) of COPD using Delphi method-
ology and to describe qualitative associations between disease attributes and their
impact on progression and outcomes. METHODS: An earlier literature review did
not identify any comprehensive CM of COPD that could be used in economic mod-
elling. A draft CM was developed based on literature and expert opinion and vali-
dated using Delphi methodology. Five experienced US and European COPD experts
were recruited and asked to describe the relationships between COPD disease at-
tributes (measurable aspects of the disease that impact on disease progression or
outcomes) included in the model using two rounds of questionnaires. Experts were
asked 1) whether the attributes included in the draft CM were relevant in explain-
ing disease progression, 2) how these attributes are associated (direction of rela-
tionship) with other attributes, 3) assess the strength of attribute-outcome rela-
tionships and 4) add additional attributes if required. Delphi results were reviewed
by a steering group of health economists, epidemiologists and clinicians to deter-
mine the attributes where sufficient evidence exists for use in economic modelling.
RESULTS: Attributes included in the final CM are exacerbations, lung function,
exercise capacity, signs/symptoms (cough, sputum, dyspnoea), co-morbidities
(CVD and depression), body composition (BMI), biomarkers (fibrinogen), smoking
history and demographic characteristics (age, gender). Mortality and quality of life
were agreed to be the most relevant (final) outcome measures. Infection, environ-
mental factors, social status and ethnicity were excluded due to lack of available
evidence to quantify their impact on disease progression and outcomes.
CONCLUSIONS: A CM should be developed prior to defining the structure of an
economic model. We developed a CM that reflects the heterogeneous nature of the
disease by including a wide variety of COPD attributes that have an impact disease
progression. Evidence is available to quantify the impact of the selected attributes
on economic, humanistic and clinical outcomes.
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OBJECTIVES: GO-RAISE clinical trial has shown Golimumab to be effective in the
treatment of severe, active ankylosing spondylitis (AS). A Markov model was de-
veloped to predict the outcomes of a cohort of AS patients treated with golimumab
50 mg (Gol) and its comparators over a 20-year time frame based on short-term
clinical trial data. We developed predictive equations for BASDAI (Bath Ankylosing
Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Func-
tional Index) to model long-term AS disease progression. METHODS: Multivariable
predictive equations of the mean change from baseline in BASDAI and BASFI scores
up to 24 weeks , and between 24–108 weeks were developed using a systematic
approach to investigate the possible non-linear functional relationships in combi-
nation with backward elimination. Fractional polynomials technique was em-
ployed to find appropriate time parameterization. To account for within-patient
correlation, a repeated measures mixed-effect model was used. Baseline score,
time and interaction of time and treatment were considered as potential predictors
along with age, sex and treatment group. Goodness of fit was evaluated with sta-
tistical and graphical methods. RESULTS: 1/Time^2 was identified as the best time
parameterization for change in both BASDAI and BASFI over the first 24 weeks. The
models depicted continuous though slight improvement in patients treated with
Gol and no change after the first eight weeks in patients treated with placebo. Log
time was identified as the best time parameterization for change in BASDAI/BASFI
from week 28 to week 108 in Gol responders group. Being on active treatment,
higher score at baseline, and male gender were associated with greater reduction in
BASDAI and BASFI score. The fitted models provided a good fit.CONCLUSIONS:The
predicted equations based on robust statistical methodology can be utilized to
model long-term AS disease progression in patients treated with anti-TNF inhib-
itors.
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OBJECTIVES: The IMS CORE Diabetes Model (CDM) is an extensively validated sim-
ulation model designed for use in both for type 1 diabetes mellitus (T1DM) and type
2 diabetes mellitus (T2DM) studies. Validation to external studies is an important
part of demonstrating model credibility, however, many studies are conducted
over a relatively short period. As the CDM is widely used to estimate long-term
clinical outcomes in diabetes patients the objective of this study was to validate the
CDM to contemporary outcomes data; including those with a 20-30 year time
horizon. METHODS: A total of 81 validation simulations were performed stratified
by duration of study follow-up (long-term defined as  15 years follow-up); for
long-term results simulation cohorts representing baseline DCCT and UKPDS co-
horts were generated and intensive and conventional treatment arms were defined
in the CDM. Predicted versus observed macrovascular and microvascular compli-
cations and all cause mortality were assessed using the coefficient of determina-
tion (R2) goodness of fit measure. RESULTS: Across all validation studies the CDM
simulations produced an R2 goodness of fit statistic of 0.90. For validation studies
with duration of follow-up15 years the CDM achieved R2 values of 0.9 and 0.88 for
T1DM and T2DM respectively. In T1DM, validating to 30-year outcomes data re-
sulted in an R2 of 0.72; for long-term 20-year validation to UKPDS in T2DM an R2 of
0.92 was obtained. CONCLUSIONS: This study supports the CDM as a credible tool
for predicting the absolute number of clinical events in DCCT and UKPDS like
populations. With increasing incidence of diabetes worldwide this is of particular
importance for health care decison makers for whom the robust evaluation of
alternative health care policies and therapeutic options is essential.
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OBJECTIVES: The need for differential discounting for costs and health outcomes
has captured the attention of many health economists. The commonly used meth-
odology for both health and money assumes a constant discount rate. The latter is
however scarcely backed up by empirical evidences on time-preference. We aim to
validly gather and interpret empirical data for a representative sample of the Dutch
population on time preference regarding different future time point. METHODS:
Sampling of 850 individuals was managed by Samplingsurvey International (Rotter-
dam NL, www.surveysamplinginternational.com). Web-based questionnaires
were developed paying particular attention to the way questions would be per-
ceived. Questions and analysis were based on a pilot study with considerations on
the possibility to elicit time preference separately for money and health and the
possibility to elicit indifference amounts for different time points in the future
regarding money and quality of life. Exclusion factor was based on the Von New-
man-Morgenstern rationality axioms assuming that consumption at different
times are different consumptions. Further sorting involved the individual’s opti-
mistic or pessimistic views about the future. RESULTS: Time-preferences for both
money and quality of life decrease, with the rate of decline also decreasing, over
increasing time of delay. The time-preference for income was found to be higher
than that of health. Individuals with low health states had higher discount rates.
Females elicited higher discount rates than males. As expected, in the short term,
optimistic individuals had higher discount rates than pessimistic ones; although
this may reverse in the longer term. More importantly, discount rate for income
was higher than that for quality of life. CONCLUSIONS: Empirical evidence col-
lected in this research indicated, similar to the pilot study, that time preferences
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